₹48.01
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Global Ventures Limited provides financial advisory and consulting services, including wealth management, investment planning, and financial planning services for individual and institutional clients.
- Sector
- Healthcare
- Industry
- Biotechnology
- HQ
- Jhajjar District, Haryana
- CEO & MD
- Yogesh Agrawal
- Registrar
- Beetal Financial & Computer Services (P) Ltd
- Exchange
- BSE
- ISIN
- INE574D01010
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Genomic Valley Biotech Ltd today?
Genomic Valley Biotech Ltd (GVBL) is trading at ₹48.01. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is GVBL’s P/E ratio versus the sector?
GVBL trades at a P/E of 1048.0. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is GVBL’s dividend yield?
GVBL has a dividend yield of 0.00%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is GVBL’s 52-week high and low?
GVBL has traded between ₹20.1 and ₹61.37 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a market capitalisation of ₹11 crore.
▶What is GVBL’s return on equity?
GVBL reports a return on equity of 0.8%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Biotechnology.
▶Who are GVBL’s competitors?
The Peers block on this page lists other Biotechnology companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is GVBL’s promoter holding?
Promoters hold 46.06% of GVBL. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include GVBL?
Index membership is listed in the Context block on this page, along with the weight GVBL carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Genomic Valley Biotech Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from GVBL’s own numbers. The judgement is yours.
GVBL at a glance
Genomic Valley Biotech Ltd operates in the Biotechnology industry, part of the Healthcare sector. Genomic Valley Biotech Ltd (GVBL) last traded at ₹48.01, giving it a market capitalisation of ₹11 crore. The 52-week range is ₹20.1 to ₹61.37, and the price is 68% of the way up that range. It trades at a price-to-earnings ratio of 1048.0. Promoters hold 46.06% of the company in the latest shareholding filing. Among 22 listed companies in the Biotechnology industry, Genomic Valley Biotech Ltd is 22nd by market capitalisation. The median price-to-earnings ratio across these companies is 48.5. Its return on equity of -0.1% compares with an industry median of 1.9%, ranking 15th of 22 peers reporting it.
| Market cap | ₹11 crore |
|---|---|
| P/E | 1048.0 |
| ROE | 0.8% |
| ROCE | 1.0% |